Scleroderma epidemiology and demographics

	Scleroderma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Scleroderma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Scleroderma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Scleroderma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Scleroderma epidemiology and demographics
CDC on Scleroderma epidemiology and demographics
Scleroderma epidemiology and demographics in the news
Blogs on Scleroderma epidemiology and demographics
Directions to Hospitals Treating Scleroderma
Risk calculators and risk factors for Scleroderma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

The incidence of scleroderma is approximately 2 per 100,000 individuals in the United States.^[1]

In 1990, the prevalence of scleroderma was estimated to be 27.6 cases per 100,000 individuals in the united states.^[2]
The prevalence of scleroderma is approximately 24 cases per 100,000 individuals in the United States.^[1]

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Patients of all age groups may develop [disease name].
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
[Chronic disease name] is usually first diagnosed among [age group].
[Acute disease name] commonly affects [age group].

Choctaw native americans from southeastern Oklahoma were reported to have much higher prevalence of scleroderma than the general population.^[3]
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Females are more commonly affected by scleroderma than males. The female to male ratio is approximately 4 to 1.^[4]

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

↑ ^1.0 ^1.1 Mayes MD (May 2003). "Scleroderma epidemiology". Rheum. Dis. Clin. North Am. 29 (2): 239–54. PMID 12841293.
↑ Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (February 2008). "Incidence and prevalence of systemic sclerosis: a systematic literature review". Semin. Arthritis Rheum. 37 (4): 223–35. doi:10.1016/j.semarthrit.2007.05.003. PMID 17692364.
↑ Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD (August 1996). "Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype". Arthritis Rheum. 39 (8): 1362–70. PMID 8702445.
↑ "Systemic scleroderma - Genetics Home Reference".